Nonresolving inflammation redux
- PMID: 35417674
- PMCID: PMC9003810
- DOI: 10.1016/j.immuni.2022.03.016
Nonresolving inflammation redux
Abstract
Nonresolving inflammation contributes to many diseases, including COVID-19 in its fatal and long forms. Our understanding of inflammation is rapidly evolving. Like the immune system of which it is a part, inflammation can now be seen as an interactive component of a homeostatic network with the endocrine and nervous systems. This review samples emerging insights regarding inflammatory memory, inflammatory aging, inflammatory cell death, inflammatory DNA, inflammation-regulating cells and metabolites, approaches to resolving or modulating inflammation, and inflammatory inequity.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The author is a co-inventor on patents related to immunoproteasome inhibitors; a scientific co-founder and equity holder in IpiNovyx, Inc; a member of the National Therapeutic Areas scientific advisory board for Pfizer External Sciences & Innovation; and a member or the scientific advisory board of Leap Therapeutics.
Figures
References
-
- Agrawal N., Bettegowda C., Cheong I., Geschwind J.F., Drake C.G., Hipkiss E.L., Tatsumi M., Dang L.H., Diaz L.A., Jr., Pomper M., et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA. 2004;101:15172–15177. doi: 10.1073/pnas.0406242101. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
